Agenus | AGEN - Operating Expenses


Agenus reported $-221.22M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Agenus USD -221.22M 241.03M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celldex Therapeutics USD 456.23M 368.95M Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 17.44B 1.53B Mar/2026
Jiangsu Hengrui CNY 5.52B 604.29M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Merck EUR 4.09B 687M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 119.99M 3.99M Mar/2026